DANTARI Trademark

Trademark Overview

On Friday, February 1, 2019, a trademark application was filed for DANTARI with the United States Patent and Trademark Office. The USPTO has given the DANTARI trademark a serial number of 88286373. The federal status of this trademark filing is REGISTERED as of Tuesday, April 11, 2023. This trademark is owned by Dantari, Inc.. The DANTARI trademark is filed in the Treatment & Processing of Materials Services category with the following description:

Biomanufacturing for others, namely, manufacturing of pharmaceuticals using biological organisms in the manufacturing process; providing technical information in the field of pharmaceutical manufacturing; custom manufacture of pharmaceuticals; custom manufacture of nanoscale material for use in the manufacture of other goods; custom manufacturing of pharmaceutical preparations for the treatment of disorders of the central nervous system; custom manufacturing of pharmaceutical preparations for the treatment of cancer; custom manufacture of pharmaceutical preparations that facilitate administration of other pharmaceutical preparations into the brain for enhanced treatment of disorders of the central nervous system and cancer
dantari

General Information

Serial Number88286373
Word MarkDANTARI
Filing DateFriday, February 1, 2019
Status700 - REGISTERED
Status DateTuesday, April 11, 2023
Registration Number7026065
Registration DateTuesday, April 11, 2023
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 3, 2019

Trademark Statements

Goods and ServicesBiomanufacturing for others, namely, manufacturing of pharmaceuticals using biological organisms in the manufacturing process; providing technical information in the field of pharmaceutical manufacturing; custom manufacture of pharmaceuticals; custom manufacture of nanoscale material for use in the manufacture of other goods; custom manufacturing of pharmaceutical preparations for the treatment of disorders of the central nervous system; custom manufacturing of pharmaceutical preparations for the treatment of cancer; custom manufacture of pharmaceutical preparations that facilitate administration of other pharmaceutical preparations into the brain for enhanced treatment of disorders of the central nervous system and cancer

Classification Information

International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateMonday, February 25, 2019
Primary Code040
First Use Anywhere DateMonday, December 21, 2020
First Use In Commerce DateThursday, November 11, 2021

Trademark Owner History

Party NameDantari, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 91320
Party NameDantari, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 91320
Party NameDantari, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWestlake Village, CA 91361

Trademark Events

Event DateEvent Description
Tuesday, April 11, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, April 11, 2023REGISTERED-PRINCIPAL REGISTER
Wednesday, March 8, 2023NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, March 7, 2023ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Monday, February 6, 2023STATEMENT OF USE PROCESSING COMPLETE
Tuesday, January 24, 2023USE AMENDMENT FILED
Tuesday, January 24, 2023TEAS STATEMENT OF USE RECEIVED
Tuesday, August 9, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 8, 2022SOU EXTENSION 5 GRANTED
Monday, July 25, 2022SOU EXTENSION 5 FILED
Saturday, August 6, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, July 25, 2022SOU TEAS EXTENSION RECEIVED
Thursday, January 20, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 18, 2022SOU EXTENSION 4 GRANTED
Tuesday, January 18, 2022SOU EXTENSION 4 FILED
Tuesday, January 18, 2022SOU TEAS EXTENSION RECEIVED
Thursday, September 2, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, September 2, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, September 2, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, July 20, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, July 17, 2021SOU EXTENSION 3 GRANTED
Saturday, July 17, 2021SOU EXTENSION 3 FILED
Saturday, July 17, 2021SOU TEAS EXTENSION RECEIVED
Wednesday, January 13, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 11, 2021SOU EXTENSION 2 GRANTED
Monday, January 11, 2021SOU EXTENSION 2 FILED
Monday, January 11, 2021SOU TEAS EXTENSION RECEIVED
Saturday, July 4, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 2, 2020SOU EXTENSION 1 GRANTED
Thursday, July 2, 2020SOU EXTENSION 1 FILED
Thursday, July 2, 2020SOU TEAS EXTENSION RECEIVED
Tuesday, January 28, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 3, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 3, 2019PUBLISHED FOR OPPOSITION
Wednesday, November 13, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, October 30, 2019ASSIGNED TO LIE
Thursday, October 24, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, October 18, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, October 16, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 16, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, April 17, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, April 17, 2019NON-FINAL ACTION E-MAILED
Wednesday, April 17, 2019NON-FINAL ACTION WRITTEN
Monday, April 15, 2019ASSIGNED TO EXAMINER
Monday, February 25, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, February 5, 2019NEW APPLICATION ENTERED

Related Keywords

dantari custom pharmaceutical manufacturing preparations manufacture treatment pharmaceuticals central disorders nervous